首页> 美国卫生研究院文献>The Oncologist >Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer

【2h】

Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer

机译：HER-2拷贝数和HER-2 / CEP-17比率与局部晚期乳腺癌中新辅助含紫杉烷类化疗敏感性的关系

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose.Aneusomy 17 causes inconsistency in fluorescence in situ hybridization (FISH)-based human epidermal growth factor receptor (HER)-2 status assessment using different algorithms (copy number or the HER-2/centromere enumerator probe 17 [CEP-17] ratio). We investigated the effects of FISH-based HER-2 status assessment and aneusomy 17 on responsiveness to neoadjuvant chemotherapy (NAC).

机译：目的。使用不同算法（拷贝数或HER-2 /着丝粒枚举探针17 [CEP-17]的比率），气肿17导致基于荧光原位杂交（FISH）的人类表皮生长因子受体（HER）-2状态评估不一致）。我们调查了基于FISH的HER-2状态评估和17气肿对新辅助化疗（NAC）反应的影响。

著录项

期刊名称 The Oncologist
作者
Ke-Da Yu; Guang-Yu Liu; Xiao-Yan Zhou; Ying Zhou; Jiong Wu; Can-Ming Chen; Zhen-Zhou Shen; Zhi-Ming Shao;
展开▼
作者单位

展开▼
年(卷),期 2012(17),6
年度 2012
页码 792–800
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Yu, K.-D.a , Liu, G.-Y.a , Zhou, X.-Y.b , Zhou, Y.a , Wu, J.a , Chen, C.-M.a , Shen, Z.-Z.a , Shao, Z.-M.a Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer [J] . YuK.-D., LiuG.-Y., ZhouX.-Y., The oncologist . 2012,第6期

机译：于克达，刘刚亚，周新来，周亚，吴雅，陈，C.-Ma，沉Z.-Za，邵Z-Ma协会局部晚期乳腺癌中HER-2拷贝数和HER-2 / CEP-17比与含新辅助紫杉烷的化疗敏感性的比较
2. Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer [J] . Ke-Da Yu, Guang-Yu Liu, Xiao-Yan Zhou, The oncologist . 2012,第6期

机译：HER-2拷贝数和HER-2 / CEP-17比值与局部晚期乳腺癌中新辅助含紫杉烷的化疗敏感性的关系
3. Alteration in steroid hormone and Her-2/ neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India [J] . Ramteke P., Seenu V, Prashad R., Indian journal of cancer. . 2016,第3期

机译：在局部晚期乳腺癌中Neoadjuvant化疗后，对类固醇激素和Her-2 / Neu受体状态的改变：在印度的高等教育中心经验
4. Clinical implications of HER-2 and p53 in taxane-based and anthracycline-based neoadjuvant chemotherapy in breast cancer [C] . World congress on breast diseases . 2008

机译：HER-2和P53在紫杉烷基和蒽环类新辅助化疗的乳腺癌中的临床意义
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab [O] . Xinle Wang, Lijing Cai, Feng Ye, -1

机译：MTDH的表达升高预示接受新辅助化疗加曲妥珠单抗的局部晚期HER-2阳性乳腺癌患者的预后更好
7. Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer [O] . E. Lattoni, C. Omarini, A.V. Tamma, 2016

机译：抗HER-2治疗时代：新辅助治疗后患者患者患者患者的单一制度分析

Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅